Capricor Therapeutics

Contributing Author

Recent Articles by Capricor Therapeutics

Sep-25	Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting CAPR GlobeNewswire
Sep-09	Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel CAPR GlobeNewswire
Aug-18	Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine CAPR GlobeNewswire
Aug-11	Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update CAPR GlobeNewswire
Aug-08	Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA CAPR GlobeNewswire
Aug-06	Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 CAPR GlobeNewswire
Jul-28	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jul-11	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jun-24	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jun-20	Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jun-17	Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program CAPR GlobeNewswire
Jun-11	Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program CAPR GlobeNewswire
May-13	Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update CAPR GlobeNewswire
May-13	Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer CAPR GlobeNewswire
May-06	Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 CAPR GlobeNewswire
May-05	Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy CAPR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.